Citrullinemia, type II, adult-onset
MONDO:0011326Adult-onset citrullinemia type II is an inherited disorder that causes ammonia and other toxic substances to accumulate in the blood. The condition chiefly affects the nervous system, causing confusion, restlessness, memory loss, abnormal behaviors (such as aggression, irritability, and hyperactivity), seizures, and coma. These signs and symptoms can be life-threatening. The signs and symptoms appear during adulthood and are triggered by certain medications, infections, surgery, and alcohol intake.The features of adult-onset type II citrullinemia may also develop in people who as infants had a liver disorder called neonatal intrahepatic cholestasis caused by citrin deficiency (NICCD). In many cases, the signs and symptoms of NICCD resolve within a year. Years or even decades later, however, some of these people develop the characteristic features of adult-onset type II citrullinemia.adult-onset citrullinemia type II is caused by mutations in the SLC25A13 gene. This condition is inherited in an autosomal recessive pattern.
Also known as: citrullinemia, adult-onset type II, citrullinemia, type II, adult-onset, CTLN2, adult-onset citrullinemia type 2, adult-onset citrullinemia type II, citrin deficiency, citrullinemia type 2, citrullinemia type II
4 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
-
One-Time gene fix could free kids from lifelong diet and meds
Disease control Recruiting nowThis early-phase trial tests a single intravenous dose of a gene editing therapy called LNP.UCD.ABE in 7 children with severe urea cycle disorders. The therapy aims to correct the genetic defect using a lipid nanoparticle to deliver a base editor. The main goal is to check safety…
Phase: PHASE1, PHASE2 • Sponsor: Rebecca Ahrens-Nicklas • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New hope for kids with rare metabolic disease: 5-Year trial launches
Disease control Recruiting nowThis study is testing a drug called glycerol phenylbutyrate in 40 Chinese children with urea cycle disorders, a rare genetic condition that causes dangerous ammonia buildup. The drug aims to help control ammonia levels over 5 years. Researchers will monitor safety and effectivene…
Sponsor: Tongji Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Simple test could unlock better monitoring for rare metabolic disorders
Diagnosis Recruiting nowThis study is testing a new way to measure how well the urea cycle works in healthy people and in patients with urea cycle disorders (UCDs). Participants receive a safe, non-radioactive tracer, and blood samples are taken over a few hours. The goal is to develop a better tool for…
Phase: NA • Sponsor: University Children's Hospital, Zurich • Aim: Diagnosis
Last updated Jun 27, 2026 08:09 UTC
-
Brain scans reveal how urea cycle disorder affects driving ability
Knowledge-focused Recruiting nowThis study uses a brain imaging technique called functional near-infrared spectroscopy (fNIRS) to observe brain activity in people with urea cycle disorder (UCD) while they perform driving tasks of varying difficulty. Researchers compare these brain patterns to those of healthy v…
Sponsor: St. Jude Children's Research Hospital • Aim: Knowledge-focused
Last updated Aug 02, 2026 00:00 UTC